Boston Scientific Q2 net sales $5.44B (+7.5% reported); adjusted EPS $0.86 beats guidance

BOSTON SCIENTIFIC CORP

Net sales $5.442B, up 7.5% reported (guidance 5.5-7.5%); adjusted EPS $0.86 (guidance $0.82-$0.84).
GAAP EPS $0.61 vs $0.53 YoY; net income $907M.
Cardiovascular segment grew 8.3% reported; MedSurg 5.9%.
Completed $2B accelerated share repurchase (~40M shares); invested $1.5B in MiRus for 34% stake and TAVR option.
Clinical data: FRACTURE IVL trial met endpoints; FARAPULSE PFA showed superiority over drugs in AVANT GUARD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.